EE526 Cost-Effectiveness Analysis of Transthyretin-Associated Amyloid Cardiomyopathy from the Brazilian Public Healthcare System Perspective
2023; Elsevier BV; Volume: 26; Issue: 6 Linguagem: Inglês
10.1016/j.jval.2023.03.2505
ISSN1524-4733
AutoresMaria João Sebastião, Pedro Antônio Muniz Ferreira, T. Senna, R.F. Alexandre, Pedro Almeida,
Tópico(s)Medication Adherence and Compliance
ResumoTransthyretin-associated amyloid cardiomyopathy (ATTR-CM) is a rare condition, caused by cardiac infiltration of amyloid fibrils, leading to organ dysfunction and, consequently, progressive heart failure. The hereditary form of the disease usually manifests itself after 47 years of age, with a median survival of 2.5 years after diagnosis for patients without treatment. The wild form affects almost exclusively older people, with a mean age at diagnosis of 74 years and a median survival from diagnosis in untreated patients of approximately 3.5 years (depending on the stage of the disease). The aim of this analysis is to compare utility and incremental costs between tafamidis and symptomatic treatment.
Referência(s)